Representative engagement
Brahma Therapeutics
Brahma Therapeutics was formed around a de novo peptide-engineering platform and the opportunity to translate foundational academic technologies into a biotechnology company.
- Challenge
- The company needed a defensible scientific and commercial foundation, access to core intellectual property, and an operating platform capable of moving from concept toward translational readiness.
- Strategic Premise
- Brahma brought foundational technologies, scientific strategy, and operating capability together to advance a new peptide-engineering platform.
- Michael's Role
- Founder & Chief Scientist. Michael negotiated foundational licenses, defined the platform and development strategy, and built the scientific operation from concept through proof of concept.
- Technology and Execution Context
- De novo peptide engineering, synthetic biology, platform strategy, translational science, intellectual-property licensing, and CMC development.
- Outcome
- Brahma was positioned for and reached a strategic acquisition outcome in May 2023.
Timeline
Company building
From intellectual property to strategic readiness
Michael connected foundational licenses, platform formation, operating capability, and translational evidence into a coherent company-building program.